Chimerix(US:CMRX) Globenewswireยท2025-03-21 10:00Core Viewpoint - The FDA's acceptance of the New Drug Application (NDA) for dordaviprone represents a significant milestone for Chimerix, providing hope for patients with recurrent H3 K27M-mutant diffuse glioma, and the acquisition by Jazz Pharmaceuticals is expected to enhance the company's ability to bring this drug to market [2][7]. Financial Results Fourth Quarter 2024 - Chimerix reported a net loss of $23.0 million, or $0.25 per share, for Q4 2024, compared to a net loss of $18.2 million, or $0.20 per share, in Q4 2023 [3][16]. - Research and development expenses rose to $17.7 million in Q4 2024 from $15.6 million in Q4 2023 [3]. - General and administrative expenses increased to $7.0 million in Q4 2024, up from $5.2 million in Q4 2023, primarily due to preparations for the commercial launch [4]. Full Year 2024 - For the full year 2024, Chimerix reported a net loss of $88.4 million, or $0.99 per share, compared to a net loss of $82.1 million, or $0.93 per share, for 2023 [5][16]. - Research and development expenses for the year increased to $74.6 million from $68.8 million in 2023 [5]. - General and administrative expenses decreased to $22.2 million for 2024, down from $24.6 million in 2023 [6]. Acquisition Details - Chimerix and Jazz Pharmaceuticals announced a definitive merger agreement on March 5, 2025, with Jazz agreeing to acquire Chimerix for $8.55 per share, totaling approximately $935 million [7]. - The transaction is expected to close in the second quarter of 2025, pending customary closing conditions [7]. Company Overview - Chimerix is a biopharmaceutical company focused on developing medicines to improve and extend the lives of patients with serious diseases, with its lead candidate, dordaviprone, targeting H3 K27M-mutant glioma [9]. - The company is also conducting Phase 1 studies for another drug, ONC206, to evaluate safety and pharmacokinetics [9].